在药物发现中向激素脱乙酶的技术:目前的进展和新兴前景
Jinxiao Ru1, Yuxi Wang2, Zijia Li1
1Department of Neurology, Joint Research Institution of Altitude Health and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
European journal of medicinal chemistry
|September 14, 2023
概括
基因组脱乙酶 (HDAC) 抑制剂在癌症治疗中表现有前途,但面临选择性和耐药性挑战. 创新的药物化学方法对于开发下一代HDAC抑制剂至关重要,以改善患者的治疗结果.
科学领域:
- 生物化学 生化学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 在瘤学瘤学.
背景情况:
- 基因脱乙酶 (HDACs) 通过表观遗传修饰来调节基因表达.
- HDACs与各种癌症有关,包括骨髓瘤和血液恶性瘤.
- 目前的HDAC抑制剂面临的挑战是选择性和耐药性.
研究的目的:
- 为癌症中HDACs提供全面的概述.
- 审查临床HDAC抑制剂的当前发展和局限性.
- 分析用于新型HDAC抑制剂开发的创新药物化学策略.
主要方法:
- 对HDAC特性,功能和抑制剂的文献综述.
- 对当前临床HDAC抑制剂开发和局限性的分析.
- 探索用于新型抑制剂设计的尖端药物化学技术.
主要成果:
- 在表观遗传调节和癌症发展中,HDACs起着至关重要的作用.
- 现有的HDAC抑制剂显示出治疗潜力,但受选择性和耐药性限制.
- 创新的策略,如选择性,双目标,蛋白质分解向金马,以及蛋白质-蛋白质相互作用抑制剂提供了新的途径.
结论:
- 新的药物化学方法对于克服当前HDAC抑制剂的局限性至关重要.
- 准HDAC仍然是癌症治疗的一个有希望的策略.
- 对先进的抑制剂设计的进一步研究可以改善临床疗效和患者的治疗结果.
相关概念视频
Drug Discovery: Overview
8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
Histone Modification
3.5K
3.5K
Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K
Spreading of Chromatin Modifications
8.3K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.3K


